GlassScriptPhysician profile
Megan James
NPI 1902688443
$2,971.73
in general payments reported to CMS, 2019-2025
33 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,597 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $409.61 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $295.95 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $239.96 | 2024-2025 | Entyvio, Trintellix |
| Abbvie INC. | $201.23 | 2024-2025 | |
| Novo Nordisk INC | $168.15 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $159.61 | 2024-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $157.98 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $148.88 | 2024 | Voquezna |
| Corcept Therapeutics | $125.00 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.21 | 2024-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $119.68 | 2025 | Watchman |
| Pfizer INC. | $98.13 | 2024-2025 | |
| Dexcom, INC. | $76.36 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $67.58 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $63.74 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $63.64 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.85 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.15 | 2025 | |
| Glaxosmithkline, LLC. | $46.12 | 2025 | Trelegy Ellipta |
| Abbott Laboratories | $45.49 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $33.21 | 2024 | |
| Amgen INC. | $31.66 | 2024 | Repatha, Otezla |
| Mylan Specialty L.P. | $31.21 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $25.55 | 2024 | Auvelity |
| Alnylam Pharmaceuticals INC. | $18.37 | 2024 | Givlaari |
| Aimmune Therapeutics, INC. | $16.93 | 2025 | Zenpep |
| Insulet Corporation | $16.33 | 2025 | Omnipod |
| Sumitomo Pharma America, INC. | $16.09 | 2025 | Gemtesa |
| Ferring Pharmaceuticals INC. | $15.67 | 2024 | Rebyota |
| Seqirus USA INC | $15.64 | 2025 | Fluad, Flucelvax |
| Grifols USA, LLC | $14.91 | 2025 | Prolastin-C Liquid |
| Sun Pharmaceutical Industries INC. | $14.10 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.74 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.